Claret Asset Management Corp Has $18.92 Million Stake in Indivior PLC $INDV

Claret Asset Management Corp lifted its position in Indivior PLC (NASDAQ:INDV) by 5.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 784,588 shares of the company’s stock after buying an additional 40,306 shares during the quarter. Indivior comprises 2.3% of Claret Asset Management Corp’s investment portfolio, making the stock its 13th largest holding. Claret Asset Management Corp owned 0.57% of Indivior worth $18,916,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Vestcor Inc acquired a new stake in Indivior in the third quarter valued at approximately $267,000. Swiss National Bank increased its stake in shares of Indivior by 1.5% during the 3rd quarter. Swiss National Bank now owns 193,431 shares of the company’s stock worth $4,664,000 after purchasing an additional 2,900 shares during the last quarter. Russell Investments Group Ltd. bought a new position in shares of Indivior during the 3rd quarter valued at $9,713,000. SPX Gestao de Recursos Ltda bought a new position in shares of Indivior during the 3rd quarter valued at $675,000. Finally, Barclays PLC lifted its stake in shares of Indivior by 1.2% in the 3rd quarter. Barclays PLC now owns 2,124,553 shares of the company’s stock valued at $51,223,000 after purchasing an additional 25,493 shares during the last quarter. Institutional investors and hedge funds own 60.33% of the company’s stock.

Insider Activity

In related news, Director Daniel A. Ninivaggi acquired 775 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were bought at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the acquisition, the director owned 16,923 shares in the company, valued at $598,904.97. This trade represents a 4.80% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David E. Wheadon acquired 1,771 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were bought at an average cost of $35.39 per share, with a total value of $62,675.69. Following the transaction, the director directly owned 14,395 shares of the company’s stock, valued at $509,439.05. The trade was a 14.03% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders acquired 4,871 shares of company stock worth $172,385.

Wall Street Analysts Forecast Growth

Several research firms have commented on INDV. HC Wainwright increased their target price on shares of Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Morgan Stanley reaffirmed an “overweight” rating and issued a $36.00 price target on shares of Indivior in a research report on Wednesday, December 3rd. Weiss Ratings raised Indivior from a “hold (c)” rating to a “buy (b-)” rating in a report on Monday, March 2nd. Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 13th. Finally, Northland Securities set a $50.00 target price on Indivior in a report on Tuesday, January 20th. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Indivior currently has an average rating of “Moderate Buy” and a consensus target price of $39.33.

Indivior Stock Up 1.0%

Shares of NASDAQ INDV opened at $32.60 on Tuesday. Indivior PLC has a 12 month low of $8.64 and a 12 month high of $38.00. The company has a market cap of $4.08 billion, a P/E ratio of 19.88 and a beta of 0.83. The business’s 50 day moving average is $34.04 and its two-hundred day moving average is $30.45.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.17. The company had revenue of $358.00 million during the quarter, compared to analysts’ expectations of $305.62 million. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%. Sell-side analysts expect that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.